Sales Performance - Immuron Limited reported strong sales growth for Travelan®, with total sales of AUD $1.5 million in the September 2024 Quarter, representing a 13% increase compared to the prior quarter [1] - Sales in Australia increased by 3% to AUD $1.007 million in the September 2024 Quarter, up from AUD $0.983 million in the June 2024 Quarter [2] - North American sales saw a significant increase of 48%, reaching AUD $0.456 million in the September 2024 Quarter compared to AUD $0.309 million in the June 2024 Quarter [3] Market Expansion - The company has secured core ranging in nine additional pharmacy banner groups in Australia, enhancing its market presence [2] - Immuron achieved its strongest monthly sales on amazon.com in the US, indicating robust demand in the North American market [2] - Distribution has expanded to ten pharmacy and grocery retailers in Canada, further solidifying the company's footprint in North America [2] Product Overview - Travelan® is an orally administered passive immunotherapy designed to reduce the likelihood of travelers' diarrhea, which is commonly caused by pathogenic bacteria [3] - The product is a purified tablet preparation of hyper-immune bovine antibodies, which bind to diarrhea-causing bacteria and prevent their colonization [3] - Travelan® is registered as a medicine in Australia and as a licensed natural health product in Canada, while in the U.S., it is marketed as a dietary supplement [3]
Immuron Travelan® continued strong sales growth